A.A. Tuleubaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A.A. Tuleubaeva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Assylzhan M. Messova
Pediatric Diseases Department, Astana Medical University, Astana 010000, Kazakhstan
3 shared publications - Sagira Abdrakhmanova
JSC «Astana Medical University», Astana, Republic of Kazakhstan
2 shared publications - A.K. Kadirova
JSC "Astana Medical University", Astana, Republic of Kazakhstan
1 shared publication - Almira I. Baigalkanova
CF «University Medical Centre», Astana, Republic of Kazakhstan
1 shared publication - Amin Tamadon
Department of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
1 shared publication - B.A. Ashirov
South Kazakhstan Medical Academy, Shymkent, Republic of Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (6) , 689
Autoimmune Thyroid Diseases After COVID-19 Infection: A Systematic Review of Clinical Manifestation and Outcomes
Background: Increasing evidence suggests that COVID-19 can induce or exacerbate autoimmune disorders, including immune-mediated thyroid dysfunction. The most common autoimmune thyroid diseases are Graves’ disease and Hashimoto’s thyroiditis; the mechanisms by which viral infections like SARS-CoV-2 trigger these diseases are not fully understood. Objectives: This study aims to systematically review published clinical evidence on the presentation, laboratory characteristics, and outcomes of autoimmune thyroid diseases after COVID-19 infection. Methods: The review followed the PRISMA 2020 framework. Scopus, Web of Science, and PubMed were searched for English-language studies between January 2020 and December 2025 using the terms COVID-19, SARS-CoV-2, autoimmune thyroiditis, Graves’ disease, Hashimoto’s thyroiditis, and autoimmune thyroid disease. Results: In total, 46 studies (five cohort studies and 41 case reports/series) involving 3856 patients were analyzed. The findings indicate that a significant increase in TPOAb prevalence occurs post-COVID-19 infection (15.7% vs. 7.7% in controls). New-onset Graves’ disease (GD) post-COVID-19 presented with higher fT3/fT4 ratios and more aggressive thyrotoxicosis compared to non-viral cases. Rare but severe manifestations included thyrotoxic periodic paralysis, Hashimoto’s encephalopathy, and dilated cardiomyopathy. Conclusions: SARS-CoV-2 may act as a trigger for autoimmune thyroid diseases, particularly in moderate-to-severe infections; however, the strength of this association warrants further investigation with controlled prospective data. Standard therapy remains effective, but thyroid function monitoring is advisable during post-COVID-19 recovery. An interdisciplinary approach is essential for early diagnosis and management of systemic complications.
- 22 May 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (6) , 689
Open AccessAutoimmune Thyroid Diseases After COVID-19 Infection: A Systematic Review of Clinical Manifestation and Outcomes
Background: Increasing evidence suggests that COVID-19 can induce or exacerbate autoimmune disorders, including immune-mediated thyroid dysfunction. The most common autoimmune thyroid diseases are Graves’ disease and Hashimoto’s thyroiditis; the mechanisms by which viral infections like SARS-CoV-2 trigger these diseases are not fully understood. Objectives: This study aims to systematically review published clinical evidence on the presentation, laboratory characteristics, and outcomes of autoimmune thyroid diseases after COVID-19 infection. Methods: The review followed the PRISMA 2020 framework. Scopus, Web of Science, and PubMed were searched for English-language studies between January 2020 and December 2025 using the terms COVID-19, SARS-CoV-2, autoimmune thyroiditis, Graves’ disease, Hashimoto’s thyroiditis, and autoimmune thyroid disease. Results: In total, 46 studies (five cohort studies and 41 case reports/series) involving 3856 patients were analyzed. The findings indicate that a significant increase in TPOAb prevalence occurs post-COVID-19 infection (15.7% vs. 7.7% in controls). New-onset Graves’ disease (GD) post-COVID-19 presented with higher fT3/fT4 ratios and more aggressive thyrotoxicosis compared to non-viral cases. Rare but severe manifestations included thyrotoxic periodic paralysis, Hashimoto’s encephalopathy, and dilated cardiomyopathy. Conclusions: SARS-CoV-2 may act as a trigger for autoimmune thyroid diseases, particularly in moderate-to-severe infections; however, the strength of this association warrants further investigation with controlled prospective data. Standard therapy remains effective, but thyroid function monitoring is advisable during post-COVID-19 recovery. An interdisciplinary approach is essential for early diagnosis and management of systemic complications.
- 28 January 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(27),p. 21-29
ASSESSMENT OF THE PROBABILITY OF DEVELOPING CARDIORENAL SYNDROME TYPE 2 DEPENDING ON POTENTIAL BIOMARKERS IN PEDIATRIC PATIENTS
Introduction. The investigation of cardiorenal syndrome holds significant clinical relevance, as both cardiovascular and renal diseases rank among the leading causes of mortality. Current research efforts are focused on identifying reliable biomarkers for the early detection of acute kidney injury (AKI), which may serve as a valuable predictor for improving prognosis and therapeutic strategies in patients with chronic heart failure. The study aims to identify biomarkers associated with an increased risk of type 2 cardiorenal syndrome in children. Materials and methods. We performed a retrospective analysis with a case-control design. From the medical records of the Scientific National Cardiac Surgery Center (NNCC), we identified all pediatric patients with CHF due to DCM who had an initial hospitalization in 2022 and a subsequent re-hospitalization in 2023. Based on their diagnosis at re-hospitalization, patients were classified into two groups: the case group (those with confirmed Type 2 CRS, n=18) and the control group (those with CHF but without CRS, n=21). We then extracted and compared laboratory data from both the 2022 (baseline) and 2023 (follow-up) hospitalizations for all participants. Results. Reduced serum iron levels were observed at baseline and during follow-up in both the control and case groups (9 and 5.9 µmol/L, respectively). Elevated total bilirubin levels were also detected in both groups (0.41 µmol/L in controls and 0.55 µmol/L in cases). Notably, galectin-3 concentrations were elevated in the case group, showing a 13% increase compared to the control group. Markers of renal dysfunction, including the albumin-to-creatinine ratio (ACR) and the blood urea nitrogen-to-creatinine (BUN/Cr) ratio, were comparable between the two groups (ACR: 31 and 32 mg/g; BUN/Cr: 30 and 32, respectively). Statistically significant correlations were identified between kidney function (as measured by ACR) and levels of serum iron (p=0.05), hemoglobin (p=0.02), and galectin-3 (p=0.02). Galectin-3 was a significant predictor of renal dysfunction, with an 81% increase in the likelihood of renal dysfunction (OR = 1.81, 95% CI). Similarly, the BUN/Cr ratio was associated with a 70% increase in the likelihood of renal impairment (OR = 1.70, 95% CI). Conclusion. The findings indicate that, despite similar baseline values of key renal markers across groups, galectin-3 levels were significantly elevated in cases and were strongly associated with renal dysfunction. Reduced serum iron and elevated bilirubin levels were observed in both groups, suggesting potential systemic involvement. However, the small sample size limits the statistical power and generalizability of these findings, warranting validation in larger, prospective cohorts. Введение. Исследование кардиоренального синдрома имеет важное клиническое значение, поскольку как сердечно-сосудистые, так и почечные заболевания входят в число основных причин смертности. Текущие исследовательские усилия сосредоточены на выявлении надежных биомаркеров для раннего выявления острого повреждения почек (ОПП), которые могут служить ценным предиктором для улучшения прогноза и терапевтических стратегий у пациентов с хронической сердечной недостаточностью. Целью исследования является выявление биомаркеров, связанных с повышенным риском кардиоренального синдрома 2 типа. Материалы и методы. Было проведено ретроспективное исследование типа «случай-контроль» с участием пациентов с подтвержденным диагнозом кардиоренального синдрома (КРС) 2-го типа (n=18) во время первичной госпитализации в 2022 г. и последующей повторной госпитализации в 2023 г., которые составили группу случая. Контрольная группа включала пациентов с хронической сердечной недостаточностью (ХСН), но без клинических или лабораторных признаков КРС 2-го типа (n=21). Результаты. Снижение уровня сывороточного железа наблюдалось на исходном уровне и во время последующего наблюдения как в группе контроля, так и в группе случая (9 и 5,9) мкмоль/л соответственно). Повышенные уровни общего билирубина также были обнаружены в обеих группах (0,41 мкмоль/л в контрольной группе и 0,55 мкмоль/л в случаях). Примечательно, что концентрации галектина-3 были повышены в группе случая, показывая 13%-ное увеличение по сравнению с контрольной группой. Маркеры почечной дисфункции, включая соотношение альбумина к креатинину (ACR) и соотношение азота мочевины крови к креатинину (BUN/Cr), продемонстрировали сопоставимые значения в обеих группах (ACR: 31 и 32 мг/г; BUN/Cr: 30 и 32 соответственно)....
- 28 January 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 6(27),p. 21-29
ASSESSMENT OF THE PROBABILITY OF DEVELOPING CARDIORENAL SYNDROME TYPE 2 DEPENDING ON POTENTIAL BIOMARKERS IN PEDIATRIC PATIENTS
Introduction. The investigation of cardiorenal syndrome holds significant clinical relevance, as both cardiovascular and renal diseases rank among the leading causes of mortality. Current research efforts are focused on identifying reliable biomarkers for the early detection of acute kidney injury (AKI), which may serve as a valuable predictor for improving prognosis and therapeutic strategies in patients with chronic heart failure. The study aims to identify biomarkers associated with an increased risk of type 2 cardiorenal syndrome in children. Materials and methods. We performed a retrospective analysis with a case-control design. From the medical records of the Scientific National Cardiac Surgery Center (NNCC), we identified all pediatric patients with CHF due to DCM who had an initial hospitalization in 2022 and a subsequent re-hospitalization in 2023. Based on their diagnosis at re-hospitalization, patients were classified into two groups: the case group (those with confirmed Type 2 CRS, n=18) and the control group (those with CHF but without CRS, n=21). We then extracted and compared laboratory data from both the 2022 (baseline) and 2023 (follow-up) hospitalizations for all participants. Results. Reduced serum iron levels were observed at baseline and during follow-up in both the control and case groups (9 and 5.9 µmol/L, respectively). Elevated total bilirubin levels were also detected in both groups (0.41 µmol/L in controls and 0.55 µmol/L in cases). Notably, galectin-3 concentrations were elevated in the case group, showing a 13% increase compared to the control group. Markers of renal dysfunction, including the albumin-to-creatinine ratio (ACR) and the blood urea nitrogen-to-creatinine (BUN/Cr) ratio, were comparable between the two groups (ACR: 31 and 32 mg/g; BUN/Cr: 30 and 32, respectively). Statistically significant correlations were identified between kidney function (as measured by ACR) and levels of serum iron (p=0.05), hemoglobin (p=0.02), and galectin-3 (p=0.02). Galectin-3 was a significant predictor of renal dysfunction, with an 81% increase in the likelihood of renal dysfunction (OR = 1.81, 95% CI). Similarly, the BUN/Cr ratio was associated with a 70% increase in the likelihood of renal impairment (OR = 1.70, 95% CI). Conclusion. The findings indicate that, despite similar baseline values of key renal markers across groups, galectin-3 levels were significantly elevated in cases and were strongly associated with renal dysfunction. Reduced serum iron and elevated bilirubin levels were observed in both groups, suggesting potential systemic involvement. However, the small sample size limits the statistical power and generalizability of these findings, warranting validation in larger, prospective cohorts. Введение. Исследование кардиоренального синдрома имеет важное клиническое значение, поскольку как сердечно-сосудистые, так и почечные заболевания входят в число основных причин смертности. Текущие исследовательские усилия сосредоточены на выявлении надежных биомаркеров для раннего выявления острого повреждения почек (ОПП), которые могут служить ценным предиктором для улучшения прогноза и терапевтических стратегий у пациентов с хронической сердечной недостаточностью. Целью исследования является выявление биомаркеров, связанных с повышенным риском кардиоренального синдрома 2 типа. Материалы и методы. Было проведено ретроспективное исследование типа «случай-контроль» с участием пациентов с подтвержденным диагнозом кардиоренального синдрома (КРС) 2-го типа (n=18) во время первичной госпитализации в 2022 г. и последующей повторной госпитализации в 2023 г., которые составили группу случая. Контрольная группа включала пациентов с хронической сердечной недостаточностью (ХСН), но без клинических или лабораторных признаков КРС 2-го типа (n=21). Результаты. Снижение уровня сывороточного железа наблюдалось на исходном уровне и во время последующего наблюдения как в группе контроля, так и в группе случая (9 и 5,9) мкмоль/л соответственно). Повышенные уровни общего билирубина также были обнаружены в обеих группах (0,41 мкмоль/л в контрольной группе и 0,55 мкмоль/л в случаях). Примечательно, что концентрации галектина-3 были повышены в группе случая, показывая 13%-ное увеличение по сравнению с контрольной группой. Маркеры почечной дисфункции, включая соотношение альбумина к креатинину (ACR) и соотношение азота мочевины крови к креатинину (BUN/Cr), продемонстрировали сопоставимые значения в обеих группах (ACR: 31 и 32 мг/г; BUN/Cr: 30 и 32 соответственно)....
- Open Access
- 28 August 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(27),p. 252-256
CASE REPORT: PAPULAR ACRODERMATOSIS OF CHILD, OR GIANOTTI-CROSTI SYNDROME
Gianotti-Crosti syndrome is a benign skin disorder, predominantly occurring in children, characterized by a symmetrical papular or papulovesicular rash localized on the face, extremities, and buttocks caused by a viral infection or hypersensitivity. We report a case of 18-month-old male child presenting with GCS with typical manifestations of this syndrome. The report offers a detailed chronology of the disease course, including the onset, evolution, and resolution of symptoms. We describe in detail the course of the disease, diagnostic signs and approach to patient management, emphasizing the importance of differential diagnosis in pediatric practice and highlighting the self-limiting nature of the syndrome. Синдром Джанотти-Крости — доброкачественное заболевание кожи, встречающееся преимущественно у детей, характеризующееся симметричной папулезной или папуловезикулярной сыпью, локализующейся на лице, конечностях и ягодицах, вызванной вирусной инфекцией или гиперчувствительностью. В статье описан случай 18-месячного мальчика с Синдромом Джанотти – Крости и типичными проявлениями этого синдрома. В работе представлена подробная хронология течения заболевания, включая начало, развитие и разрешение симптомов. Мы подробно описываем течение заболевания, диагностические признаки и подход к ведению пациента, подчеркивая важность дифференциальной диагностики в педиатрической практике и подчеркивая самоограничивающийся характер синдрома Джанотти–Крости синдромы - негізінен балаларда кездесетін, симметриялы папулалық немесе папуловезикулярлы бөртпелермен сипатталатын терінің қатерсіз зақымдануы. Бөртпелер әдетте аяқ-қолдарда, бетте және жамбас аймағында орналасады. Синдромның дамуында вирустық инфекциялар немесе жоғары сезімталдық реакциялары басты этиологиялық факторлар ретінде қарастырылады. Мақалада Джанотти-Крости синдромы бар 18 айлық баланың жағдайы және осы синдромның типтік көріністері сипатталған. Жұмыста аурудың басталуын, дамуын және симптомдардың шешілуін қоса алғанда, аурудың ағымының егжей-тегжейлі хронологиясы берілген. Аурудың клиникалық ағымы, диагностикалық ерекшеліктері және емдеу мен бақылау тәсілдері егжей-тегжейлі баяндалып, педиатриялық тәжірибеде дифференциалды диагностиканың маңыздылығы мен синдромның өздігінен шектелетін табиғаты атап өтіледі.
- 28 August 2025
- Published by Semey Medical University in Наука и здравоохранение
- No. 4(27),p. 252-256
Open AccessCASE REPORT: PAPULAR ACRODERMATOSIS OF CHILD, OR GIANOTTI-CROSTI SYNDROME
Gianotti-Crosti syndrome is a benign skin disorder, predominantly occurring in children, characterized by a symmetrical papular or papulovesicular rash localized on the face, extremities, and buttocks caused by a viral infection or hypersensitivity. We report a case of 18-month-old male child presenting with GCS with typical manifestations of this syndrome. The report offers a detailed chronology of the disease course, including the onset, evolution, and resolution of symptoms. We describe in detail the course of the disease, diagnostic signs and approach to patient management, emphasizing the importance of differential diagnosis in pediatric practice and highlighting the self-limiting nature of the syndrome. Синдром Джанотти-Крости — доброкачественное заболевание кожи, встречающееся преимущественно у детей, характеризующееся симметричной папулезной или папуловезикулярной сыпью, локализующейся на лице, конечностях и ягодицах, вызванной вирусной инфекцией или гиперчувствительностью. В статье описан случай 18-месячного мальчика с Синдромом Джанотти – Крости и типичными проявлениями этого синдрома. В работе представлена подробная хронология течения заболевания, включая начало, развитие и разрешение симптомов. Мы подробно описываем течение заболевания, диагностические признаки и подход к ведению пациента, подчеркивая важность дифференциальной диагностики в педиатрической практике и подчеркивая самоограничивающийся характер синдрома Джанотти–Крости синдромы - негізінен балаларда кездесетін, симметриялы папулалық немесе папуловезикулярлы бөртпелермен сипатталатын терінің қатерсіз зақымдануы. Бөртпелер әдетте аяқ-қолдарда, бетте және жамбас аймағында орналасады. Синдромның дамуында вирустық инфекциялар немесе жоғары сезімталдық реакциялары басты этиологиялық факторлар ретінде қарастырылады. Мақалада Джанотти-Крости синдромы бар 18 айлық баланың жағдайы және осы синдромның типтік көріністері сипатталған. Жұмыста аурудың басталуын, дамуын және симптомдардың шешілуін қоса алғанда, аурудың ағымының егжей-тегжейлі хронологиясы берілген. Аурудың клиникалық ағымы, диагностикалық ерекшеліктері және емдеу мен бақылау тәсілдері егжей-тегжейлі баяндалып, педиатриялық тәжірибеде дифференциалды диагностиканың маңыздылығы мен синдромның өздігінен шектелетін табиғаты атап өтіледі.